Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy.

[1]  V. Kuchroo,et al.  Interleukin-17 and type 17 helper T cells. , 2009, The New England journal of medicine.

[2]  D. Hafler,et al.  Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells1 , 2009, The Journal of Immunology.

[3]  D. Bending,et al.  Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. , 2009, The Journal of clinical investigation.

[4]  J. Manson,et al.  Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial , 2008, Diabetes Care.

[5]  S. Doucette,et al.  The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  S. Maeda.  Do inflammatory cytokine genes confer susceptibility to diabetic nephropathy? , 2008, Kidney international.

[7]  S. Shankland,et al.  Proteinuria in diabetic kidney disease: a mechanistic viewpoint. , 2008, Kidney international.

[8]  M. Mauer,et al.  The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007 , 2008, Diabetologia.

[9]  Su-Yen Goh,et al.  The role of advanced glycation end products in progression and complications of diabetes , 2008 .

[10]  G. Tesch.  MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[11]  J. Navarro-González,et al.  The role of inflammatory cytokines in diabetic nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[12]  P. Fioretto,et al.  The Kidney in Diabetes: Dynamic Pathways of Injury and Repair , 2007 .

[13]  B. Rollins,et al.  Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice , 2007, Diabetologia.

[14]  G. Wolf,et al.  Advanced glycation end products and the kidney , 2005 .

[15]  G. Wolf.  New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology , 2004, European journal of clinical investigation.

[16]  G. Jerums,et al.  Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  J. Egido,et al.  Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. , 2003, Kidney international. Supplement.

[18]  C. Forsblom,et al.  Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients , 2003, Diabetologia.

[19]  E. Ritz,et al.  Diabetic nephropathy in type 2 diabetes prevention and patient management. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  F. Cipollone,et al.  Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. , 2002, Diabetes care.

[21]  Giuseppe Remuzzi,et al.  Nephropathy in Patients with Type 2 Diabetes , 2002 .

[22]  M. Kitamura,et al.  Role of High Glucose–induced Nuclear Factor–␬b Activation in Monocyte Chemoattractant Protein-1 Expression by Mesangial Cells , 2001 .

[23]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  M. Cooper,et al.  Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy , 2001, Diabetologia.

[25]  J. Egido,et al.  Tubular NF-κB and AP-1 activation in human proteinuric renal disease , 2001 .

[26]  L. Beilin,et al.  Advanced glycation end-products: a review , 2001, Diabetologia.

[27]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[28]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[29]  F. Locatelli,et al.  End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  J. Pickup,et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X , 1997, Diabetologia.

[31]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[32]  K. Ley,et al.  Leukocyte recruitment and vascular injury in diabetic nephropathy. , 2006, Journal of the American Society of Nephrology : JASN.

[33]  J. Gross,et al.  Diabetic nephropathy: diagnosis, prevention, and treatment. , 2005, Diabetes care.

[34]  R. Zatz,et al.  Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. , 2003, Kidney international.

[35]  Giuseppe Remuzzi,et al.  Clinical practice. Nephropathy in patients with type 2 diabetes. , 2002, The New England journal of medicine.

[36]  J. Egido,et al.  Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. , 2001, Kidney international.